Cancer Diagnostics Market by Testing Methods – Biopsy Tests (Bone Marrow, Endoscopic, Needle Biopsy), Endoscopy Tests (Bronchoscopy, Colonoscopy, Colposcopy, Sigmoidoscopy), Diagnostic Imaging (CT, MRI, PET, Mammography, Ultrasound), and Detection of Cancer-Specific Tumor Biomarkers) and Applications (Organ or Cell-Specific Cancer Types – Blood, Breast, Colorectal, Kidney, Liver, Lung, Ovarian, Pancreatic, and Prostate Cancer) and Forecast 2017-2021

Cancer Diagnostics Market by Testing Methods – Biopsy Tests (Bone Marrow, Endoscopic, Needle Biopsy), Endoscopy Tests (Bronchoscopy, Colonoscopy, Colposcopy, Sigmoidoscopy), Diagnostic Imaging (CT, MRI, PET, Mammography, Ultrasound), and Detection of Cancer-Specific Tumor Biomarkers) and Applications (Organ or Cell-Specific Cancer Types – Blood, Breast, Colorectal, Kidney, Liver, Lung, Ovarian, Pancreatic, and Prostate Cancer) and Forecast 2017-2021

There are many different ways to diagnose cancer. Cancer diagnostic testing involves tests and procedures to confirm the presence of disease and identify the correct tumor type, location, extent and stage. The most common diagnostic tests include biopsy tests (bone marrow, endoscopic, needle biopsy), endoscopy tests (bronchoscopy, colonoscopy, colposcopy, sigmoidoscopy, etc.), diagnostic imaging (CT, MRI, PET, mammography, ultrasound, etc.), and detection of cancer-specific tumor biomarkers.  Benign tumors are slow growing tumors and do not invade into other tissues while the malignant tumors are characterized by rapid growth, invasiveness, and potential to colonize in distant organs. The rising prevalence of cancer across the globe is driving the global cancer diagnostics market, whereas higher incidences of cancer and increasing healthcare spending is expected to aid the global tissue diagnostics market.

The global cancer diagnostics market report estimates the market size (Revenue US$ million – 2014 to 2021) for market segmentation based on testing methods and their applications (organ or cell-specific cancer types – blood, breast, colorectal, kidney, liver, lung, ovarian, pancreatic, and prostate cancer) and forecasts growth trends (CAGR% – 2017 to 2021).

The global cancer diagnostics market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global cancer diagnostics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global cancer diagnostics market and included in this report are Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Genentech, Genoptix (Novartis), and Roche Diagnostics.

  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue US$ Million, 2014-2021)
    • Forecast Estimation (Revenue US$ Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Products
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Diagnostic Test Type
    • Indication or Infection Type
    • Technology
    • Diagnostics Application
    • Service Type
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • Device Classification I, II, III, IV
    • Device (FDA, EMEA) Approvals
  8. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  9. Recommendations
  10. References

Cancer Diagnostic Testing Market

1. Diagnostic Test
1.1. Biopsy
1.1.1. Bone Marrow Biopsy
1.1.2. Endoscopic Biopsy
1.1.3. Needle Biopsy
1.2. Endoscopy
1.2.1. Bronchoscopy
1.2.2. Colonoscopy
1.2.3. Colposcopy
1.2.4. Sigmoidoscopy
1.2.5. Others
1.3. Diagnostic Imaging
1.3.1. Computed Tomography (CT) Scan
1.3.2. Magnetic Resonance Imaging (MRI) Scan
1.3.3. Mammography
1.3.4. Positron Emission Tomography (PET) Scan
1.3.5. Ultrasound
1.4. Tumor Biomarker
1.4.1. Alpha-Fetoprotein (AFP) Tests
1.4.2. Anaplastic Lymphoma Kinase (ALK) Tests
1.4.3. BRCA Tests
1.4.4. CA 125 Tests
1.4.5. CA 19-9 Tests
1.4.6. Carcinoembryonic Antigen (CEA) Tests
1.4.7. Circulating Tumor Cells (CTC) Tests
1.4.8. EGFR Mutation Tests
1.4.9. HER2 Tests
1.4.10. KRAS Mutation Tests
1.4.11. Prostate Specific Antigen Tests

2. Application (Cancer Type)
2.1. Blood Cancer
2.2. Breast Cancer
2.3. Colorectal Cancer
2.4. Kidney Cancer
2.5. Liver Cancer
2.6. Lung Cancer
2.7. Ovarian Cancer
2.8. Pancreatic Cancer
2.9. Prostate Cancer

3. Company Profiles
3.1. Abbott Laboratories, Inc.
3.2. Ambry Genetics
3.3. AstraZeneca plc
3.4. bioMeriux SA
3.5. Eli Lilly and Company
3.6. Genoptix, Inc.
3.7. GlaxoSmithKline plc
3.8. Hoffmann-La Roche Ltd.
3.9. Pfizer, Inc.

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*